Fluxapyroxad (FLU), a widely used succinate dehydrogenase inhibitor (SDHI) fungicide, can enter aquatic environments and pose potential risks to aquatic organisms. This study investigated the hepatotoxic effects of long-term FLU exposure in adult zebrafish exposed to 0, 30, 60, and 90 μg/L FLU for 28 days. High-dose (90 μg/L) exposure significantly reduced body weight, increased liver weight, and induced hepatic vacuolization and reduced glycogen storage in histological analysis. Transcriptomic analysis of the high-dose group revealed significant upregulation of lipid metabolism-related genes (ldlr, lpin1, apoc2), enriched in PPAR signaling and non-alcoholic fatty liver disease pathways; lipidomic profiling showed widespread lipid alterations (especially phosphatidylcholine species), with glycerophospholipid metabolism as the most affected pathway, and 11 differential lipid species including PC(18:0/16:0) and TG(20:0/14:0/14:0) were identified as candidates. Integrated multi-omics analysis demonstrated that high-dose FLU exposure triggered hepatic lipid metabolic disorders via dysregulated expression of genes involved in lipid synthesis, transport and degradation. These findings reveal the mechanism of FLU-induced hepatotoxicity, and provide reference for identifying FLU-responsive hepatic differential lipids, as well as ecological risk assessment of FLU and related SDHI fungicides in aquatic systems.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: